UK Government Plays Matchmaker In GSK/Novavax Deal To ‘Onshore’ COVID-19 Vaccine Production
Comes Amid Tensions With EU
The UK wants to consolidate its rapid vaccine roll-out and its domestic supply chain via the alliance
You may also be interested in...
Top-line Phase II data show that a combo of bamlanivimab and VIR-7831, neutralizing antibodies to the SARS-CoV-2 spike protein, yielded a relative 70% reduction in viral load.
Investors are anxious about the delay to Novavax’s deal with the EU, and want to know how and when it might file the vaccine with regulators.
The UK biotech aims to raise $100m, but will need to tackle safety concerns to secure a long-term future.